Biểu đồ giá cổ phiếu PROK
PROK Tài chính
Prokidney Corp
$1.64
-1.2%
$-0.02
Khi đóng cửa: Jun 12, 16:00:00 GMT-4
$1.64
0%
$0
Phiên sau giờ: Jun 12, 20:00:00 GMT-4
Quay lại
Prokidney Corp (PROK) Tài chính
Thống kê chính
Giá đóng cửa trước
$1.66
Giá mở cửa
$1.65
Phạm vi ngày
$1.61 - $1.71
Phạm vi 52 tuần
$0.54 - $7.13
Khối lượng
773.7K
Khối lượng trung bình
884.3K
Tỷ suất cổ tức
--
EPS (TTM)
-0.51
Vốn hóa thị trường
$495.1M
PROK là gì?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 231 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
